Dr. Niv Papo - Publications
1- Wasserman, M. S , Yagen, B. PI , Blotnik, S. PD , Papo, N. S , and Bialer, M. PI (2001)
“Stereoselective Pharmacokinetic Analysis and Antiepileptic Activity of N-2-hydroxypropyl
Valpromide, a Central Nervous System-Active Chiral Valproylamide.” Ther. Drug Monit.
23, 414-420.
2- Papo, N. S , Oren, Z. S , Pag, U. S , Sahl, H.G. PI , and Shai, Y PI . (2002) “The Consequence of
Sequence Alteration of an Amphipathic Alpha-Helical Antimicrobial Peptide and its
Diastereomers.” J. Biol. Chem. 277, 33913-33921.
3- Papo, N. S and Shai, Y. PI (2003) “Exploring Peptide Membrane Interaction Using Surface
Plasmon Resonance: Differentiation between Pore Formation versus Membrane Disruption
by Lytic Peptides.” Biochemistry 42, 458-466.
4- Papo, N. S , Shahar, M. T , Eisenbach, L. PI , and Shai, Y. PI (2003) “A Novel Lytic Peptide
Composed of D, L Amino Acids Selectively Kills Cancer Cells in Culture and in Mice.” J.
Biol. Chem. 278, 21018-21023.
5- Papo, N. S and Shai, Y. PI (2003) “New Lytic Peptides Based on D,L-Amphipathic Helix Motif
Preferentially Kill Tumor Cells Copmpared to Normal Cells.” Biochemistry 42, 9346-9354.
6- Mangoni, M.L. S , Papo, N. S , Mignogna, G. S , Andreu, D. S , Shai, Y. PI , Barra, D. PI , and Simmaco,
M. PI (2003) “Ranacyclins, a New Family of Short Cyclic Antimicrobial Peptides: Biological
Function, Mode of Action and Parameters Involved in Target Specificity.” Biochemistry 42,
14023-14035.
7- Papo, N. S and Shai, Y. PI (2003) “Can We Predict Biological Activity of Antimicrobial
Peptides from their Interactions with Model Phospholipid Membranes?” Peptides 24, 1693-
1703.
8- Pag, U. S , Oedenkoven, M. S , Papo, N. S , Oren, Z. S , Shai, Y. PI , and Sahl, H.G PI . (2004) “In Vitro
Activity and Mode of Action of Diastereomeric Antimicrobial Peptides against Bacterial
Clinical Isolates.” J. Antimicrob. Chemother. 53, 230-239.
9- Papo, N. S and Shai, Y PI . (2004) “Effect of Drastic Sequence Alteration and D-amino Acid
Incorporation on the Membrane Binding Behavior of Lytic Peptides.” Biochemistry 43, 6393-
6403.
10- Mangoni, M.L. S , Papo, N. S , Barra, D. PI , Simmaco, M. PI , Bozzi, A. S , Di Giulio, A. S , and
Rinaldi, A.C. PI (2004) “Effects of the Antimicrobial Peptide Temporin L on Cell Morphology,
Membrane Permeability, and Viability of Escherichia coli.” Biochem. J. 380, 859-865.
11- Braunstein, A. §PD , Papo, N. §S and Shai, Y. PI ( § equal contribution) (2004) “In Vitro Activity
and Potency of an Intravenously Injected Antimicrobial Peptide and its D,L Amino Acid
Analog on Mice Infected with Bacteria.” Antimicrob. Agent Chemother. 48, 3127-3129.
12- Papo, N. § S, Braunstein, A. §PD , Eshhar, Z. PI , and Shai, Y. PI ( § equal contribution) (2004)
“Suppression of Human Prostate Tumor Growth in Mice by a Cytolytic D-, L-amino Acid
Peptide: Membrane Lysis, Increased Necrosis, and Inhibition of Prostate-Specific Antigen
Secretion.” Cancer Res. 64, 5779-5786.
13- Papo, N. S and Shai, Y. PI (2005) “A Molecular Mechanism for Lipopolysaccharide Protection
of Gram-Negative Bacteria from Antimicrobial Peptides.” J. Biol. Chem. 280, 10378-10387.
14- Zelezetsky, I. S , Pacor, S. S , Pag, U. S , Papo, N. S , Shai, Y. PI , Sahl, H.G. PI , and Tossi, A. PI (2005)
“Controlled Alteration of the Shape and Conformational Stability of Alpha-Helical Cell-Lytic
Peptides: Effect on Mode of Action and Cell Specificity.” Biochem. J. 390, 177-188.
15- Papo, N. S and Shai, Y. PI (2005) “Host Defense Peptides as New Weapons in Cancer
Treatment.” Cellular and Molecular Life Sciences 62, 784-790.
16- Tomasinsig, L. S , Skerlavaj, B. S , Papo, N. S , Giabbai, B. S , Shai. Y. PI , and Zanetti, M. PI
(2006) “Mechanistic and functional studies of the interaction of a proline-rich antimicrobial
peptide with mammalian cells.” J. Biol. Chem. 281, 383-391.
17- Carmieli, R. S , Papo, N. S , Zimmermann, H. S , Potapov, A. S , Shai, Y. PI , and Goldfarb, D. PI (2006)
“Utilizing ESEEM Spectroscopy to Locate the Position of Specific Regions of Membrane
Active Peptides within Model Membranes.” Biophys. J. 90, 492-505.
18- Rosenfeld, Y. S , Papo, N. S , and Shai, Y. PI (2006) “Endotoxin (LPS) Neutralization by Innate
Immunity Host-Defense Peptides: Peptide’s Properties and Plausible Modes of Action.” J.
Biol. Chem. 281, 1636-1643.
19- Mangoni, M.L. S , Papo, N. S , Saugar, J.M. S , Barra, D. PI , Shai, Y. PI , Simmaco, M. PI , and Rivas,
L. PI (2006) “Effect of Natural L- to D-Amino Acid Conversion on the Organization,
Membrane Binding and Biological Function of the Antimicrobial Peptides Bombinins H.”
Biochemistry 45, 4266-4276.
20- Papo, N. S , Seger, D. T , Makovitzki, A. S , Kalchenko, V. S , Eshhar, Z. PI , Degani, H. PI , and Shai,Y.
PI (2006) “Inhibition of Tumor Growth and Elimination of Multiple Metastases in Human
Prostate and Breast Xenografts by Systemic Inoculation of a Host-Defense-Like Lytic
Peptide.” Cancer Res. 66, 5371-5378.
21- Kipnis, Y. §S , Papo, N. §PD , Haran, G. PI , and Horovitz, A. PI ( § equal contribution) (2007)
“Concerted ATP-induced Allosteric Transitions in GroEL Facilitate Release of Protein
Substrate Domains in an All-or-None Manner.” Proc. Natl. Acad. Sci. U.S.A. 104, 3119-
3124.
22- Papo, N. §PD , Kipnis, Y. §S , Haran, G. PI , and Horovitz, A. PI ( § equal contribution) (2008)
“Concerted release of substrate domains from GroEL by ATP is demonstrated with FRET.”
J. Mol. Biol. 380, 717-725.
23- Papo, N. PD , Silverman, A.P. PD , Lahti, J.L. S , and Cochran, J.R. PI (2011) “Antagonistic VEGF
Variants Engineered to Simultaneously Bind to and Inhibit VEGFR2 and α v β 3 Integrin”. Proc.
Natl. Acad. Sci. U.S.A. 108, 14067-14072.
* 24- Rosenfeld, L. S , Shirian, J S ., Zur, Y. S , Levaot, N. C , Shifman, J.M. C , and Papo. N. PI , (2015)
“Combinatorial and computational approaches to identify interactions of macrophage colony
stimulating factor (M-CSF) and its receptor c-fms.” Journal of Biological Chemistry. 290,
26180-93.
* 25- Cohen I. S , Kayode O. S , Hockla A. S , Sankaran B. S , Radisky D. T , Radisky E. C , and Papo N. PI ,
(2016) Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors
as candidates for cancer therapy. Biochem. J. 473, 1329-41.
* 26- Rosenfeld, L. S , Heyne, M. S , Shifman, J.M. C , and Papo. N. PI (2016) Protein engineering with
combined combinatorial and computational approaches. Trends in Biochemical Sciences. 41,
421-33.
* 27- Mohan V. S , Talmi Frank D. S , Koshelev V. S , Papo N PI . and Sagi I. PI , (2016) Matrix
Metalloproteinase Protein Inhibitors: Highlighting a New Beginning for Metalloproteinases in
Medicine. Journal Metalloproteinases in Medicine. 3, 31-47.
* 28- Banerjee V. S , Shani T. S , Katzman B. S , Vyazmensky M. S , Papo N. C , Israelson A. C and Engel
S. PI (2016) SOD1–derived peptide induces SOD1 misfolding and inhibits amyloid-like
aggregation of misfolded SOD1. ACS Chem Neurosci. 7(11):1595-1606.
* 29- Dalton A.C. S , Shlamkovitch T. S , Papo N. C , and Barton W.A. PI , (2016) Tie and Integrin
Signaling Pathways Coordinate to Regulate the Angiogenic Switch. PLOS One.
11(10):e0163732.
* 30- Olumide Kayode S , Ruiying Wang S , Devon F. Pendlebury S , Itay Cohen S , Rachel D. Henin S ,
Alexandra Hockla S , Alexei S. Soares S , Niv Papo C , Thomas R. Caulfield C , and Evette S.
Radisky PI , (2016) An acrobatic substrate metamorphosis reveals a requirement for substrate
conformational dynamics in trypsin proteolysis. JBC. 291(51):26304-26319.
* 31- Rabinovich E. S , Heyne M. S , Bakhman A. S , Kosloff M. C , Shifman J. C , and Papo N. PI (2017).
Identifying ligand-receptor interactions at the residue level through a combination of
experimental and in silico mutagenesis analysis. Journal of Molecular Biology. 429(1):97-
114.
* 32- Valeria Arkadash S , Gal Yosef S , Jason Shirian S , Itay Cohen S , Yuval Horev S , Moran Grossman S ,
Irit Sagi C , Evette S. Radisky C , Julia M. Shifman C , and Niv Papo PI (2017). Development of
high-affinity and high-specificity inhibitors of MMP-14 through computational design and
directed evolution. JBC. 292(8):3481-3495.
* 33- Kapur, Shiven PD ; Silverman, Adam PD ; Ye, Anne S ; Papo, Niv C ; Jindal, Darren S ; Blumenkranz,
Mark S ; Cochran, Jennifer PI (2017). Engineered ligand-based VEGFR antagonists with
increased receptor binding affinity more effectively inhibit angiogenesis. Bioengineering &
Translational Medicine. 2(1): 81-91.
* 34- Papo. N. PI and Shifman, J.M. PI (2017). Engineering and Design. Editorial. Current Opinion in
Structural Biology. 45:iv-vi.
* 35- Tomer Shlamkovitch S , Lidan Aharon S , William A. Barton C and Niv Papo PI (2017). Utilizing
combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as
candidates for anti-angiogenesis therapy. Oncotarget. 8(20):33571-33585.
* 36- Yuval Zur S , Lior Rosenfeld S , Anna Bakhman S , Stefan Ilic S , Hezi Hayun S , Anat Shahar S , Barak
Akabayov C , Mickey Kosloff C , Noam Levaot C , and Niv Papo PI (2017). Engineering a
monomeric variant of macrophage colony-stimulating factor (MCSF) that antagonizes the c-
FMS receptor. Biochemical Journal. 474(15):2601-2617.
* 37- Banerjee V. S , Oren O. S , Taube R. C , Engel S. C , and Papo N. PI (2017) A computational
combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding,
aggregation and cytotoxicity. JBC. 292(38):15777-15788.
* 38- Shvil N. S , Banerjee V. PD , Zoltsman G. S , Shani T. S , Kahn J. T , Abu-Hamad S. S , Papo N. C , Engel
S. C , Bernhagen J. C and Adrian Israelson PI , (2018) Macrophage migration inhibitory factor
inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: implications for
familial ALS. Cell Death and Disease. 9(2):107.
* 39- Jason Shirian S , Valeria Arkadash S , Itay Cohen S , Evette S. Radisky C , Niv Papo PI and Julia M.
Shifman PI (2018). Computational and Combinatorial Design of N-TIMP-2 for Specific
Inhibition of Matrix Metalloproteinases. FEBS Lett. In press.
* 40- Cohen I. S , Naftali S. S , Ben-Zeev E T , Hockla A. S , Radisky E. C , and Papo N. PI (2018) Pre-
Equilibrium Competitive Library Screening for Tuning Inhibitor Association Rate and
Specificity towards Serine Proteases. Biochem. J. In press.
* 41- Dana Koslawsky S , Marianna Shitrit-Zaretsky T , Ron Alcalay T , Ohad Mazor T , Amir
Aharoni C and Niv Papo PI (2018). A bi-specific inhibitor targeting IL-17A and MMP-9
reduces invasion and motility in MDA-MB-231 cells. Oncotarget. 292(38):28500-28513.
* 42- Yuval Zur S , Lior Rosenfeld S , Nofar Dalal, Gali Guterrman S , Yulia Einav C , Noam
Levaot C , and Niv Papo PI (2018). A dual-specific macrophage colony stimulating factor
antagonist that inhibits c-FMS and αvβ3 integrin for osteoporosis therapy. PLOS Biology. In
press.
* 43- Sananas A. S , Cohen I. S , Shahar A. T , Radisky E. C , and Papo N. PI (2018) A selective,
proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy,
developed by combinatorial engineering. JBC. In press.
* 44- Gal Yosef S , Valeria Arkadash S , and Niv Papo PI (2018). Developing multispecific N-
TIMP2 antagonistic monomers and heterodimers that target MMP-14 and v3 integrin for
Cancer Therapy. JBC. In press.
* 45- Valeria Arkadash S , Evette S. Radisky C and Niv Papo PI (2018). Combinatorial
engineering of N-TIMP2 variants that selectively inhibit MMP9 and MMP14 function in the
cell. Oncotarget. In press.
* 46- Tomer Shlamkovitch S , Lidan Aharon S , Dana Koslawsky S , Yulia Einav C and Niv Papo PI
(2017). Targeting the Tie2-αvβ3 integrin axis with bispecific reagents for the inhibition of
angiogenesis. BMC Biology. In press.